Use of aspirin and P2Y 12 inhibitors in patients with atherosclerotic cardiovascular disease (ECVA)
DOI:
https://doi.org/10.47187/cssn.Vol14.Iss2.204Keywords:
atherosclerosis, myocardial ischemia, platelet aggregation inhibitorsAbstract
Introduction: Atherosclerotic cardiovascular disease (ACVD) is a chronic and progressive disorder that affects the heart and medium- and large-caliber arteries as a consequence of atherosclerosis, its most frequent forms of presentation being ischemic heart disease and cerebrovascular disease. Antiplatelet agents, aspirin, and P2Y 12 inhibitors are used for primary and secondary prevention of ACVD. Objective: To analyze the efficacy of aspirin and P2Y 12 inhibitors in patients with atherosclerotic cardiovascular disease. Methodology: a bibliographic review on the use of aspirin and P2Y12 inhibitors in ACVD was carried out, for which trials chosen according to inclusion and exclusion criteria were used. Results: 6 original studies were found that compare or expose the efficacy of aspirin and P2Y12 inhibitors. Discussion: Studies show that aspirin continues to be the drug of choice in the treatment of ACVD. P2Y12 inhibitors have also reported benefits, the most documented being clopidogrel and ticagrelor. Conclusions: The use of aspirin as therapy for the primary prevention of ACVD currently has low evidence of its benefit, however, for secondary prevention therapy it is well documented and its best effect is observed when combined with P2Y12 inhibitors.
Downloads
References
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nature reviews [Internet]. 2019 Jul 16 [cited 2022 Jul 14];5(1):1–18. Available from: https://pubmed.ncbi.nlm.nih.gov/31420554/
Sarre-Álvarez D, Cabrera-Jardines R, Rodríguez-Weber F, Díaz-Greene E, Sarre-Álvarez D, Cabrera-Jardines R, et al. Enfermedad cardiovascular aterosclerótica. Revisión de las escalas de riesgo y edad cardiovascular. Medicina interna de México [Internet]. 2018 Dec [cited 2022 Jul 14];34(6):910–23. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662018000600010&lng=es&nrm=iso&tlng=es
Olie RH, van der Meijden PEJ, Spronk HMH, ten Cate H. Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Springer Link [Internet]. 2022 Aug 11 [cited 2022 Jul 14];270:103–30. Available from: https://link.springer.com/chapter/10.1007/164_2020_357
Loaiza WM, Ruiz AKR, Vivas MC. Factores involucrados en la enfermedad cardiovascular aterosclerótica y su potencial utilidad como biomarcadores. Revista Médica de Rosario [Internet]. 2021 Jan 19 [cited 2022 Jun 5];86(3):152–64. Available from: http://revistamedicaderosario.org/index.php/rm/article/view/114
Lahoz C, Mostaza JM. La aterosclerosis como enfermedad sistémica. Revista Española de Cardiología [Internet]. 2017 Feb 1 [cited 2022 Jun 5];60(2):184–95. Available from: http://www.revespcardiol.org/es-la-aterosclerosis-como-enfermedad-sistemica-articulo-13099465
Luis Mayorga-Butrón J, López-Juárez N, Cruz-Bautista I. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica Carotid artery disease View project Nutrition View project. 2022 [cited 2022 Jun 5]; Available from: https://www.researchgate.net/publication/359147316
Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FAR, et al. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Annals of Internal Medicine. 2016 Jun 21;164(12):836–45.
Categoría de riesgo de enfermedad cardiovascular | Rivera Ledesma | Revista Cubana de Medicina General Integral [Internet]. [cited 2022 Jun 5]. Available from: http://www.revmgi.sld.cu/index.php/mgi/article/view/450
Sarre-Álvarez D, Cabrera-Jardines R, Rodríguez-Weber F, Díaz-Greene E, Rodríguez Weber F. Correspondencia. [cited 2022 Jun 5]; Available from: www.medicinainterna.org.mx
Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal. 2018 Apr 1;198:135–44.
La enfermedad cardiovascular aterosclerótica desde la niñez a la adultez | Liapur Milián | Revista Cubana de Pediatría [Internet]. [cited 2022 Jun 5]. Available from: http://www.revpediatria.sld.cu/index.php/.ped/article/view/389
González-Rincón M, Curiel G, Barreto K, Ruiz A, Quintero J, Sánchez MP, et al. Factores de crecimiento en plasma rico en plaquetas de individuos sanos tratados con agentes antiplaquetarios. FACSALUD-UNEMI [Internet]. 2022 Jun 6 [cited 2022 Jul 17];6(10):58–68. Available from: https://ojs.unemi.edu.ec/index.php/facsalud-unemi/article/view/1579
Quiroga Narváez J, Chertcoff A, Pantiú F, León Cejas L, Bonardo P, Uribe Roca C, et al. Hemorragia intracraneal asociada a tratamiento antiplaquetario dual con ticagrelor. Neurología Argentina [Internet]. 2018 Apr 1 [cited 2022 Jul 17];10(2):103–5. Available from: https://www.elsevier.es/es-revista-neurologia-argentina-301-articulo-hemorragia-intracraneal-asociada-tratamiento-antiplaquetario-S1853002816300969
Arias JKB, Arias JKB, Avila KNG, Moyon LJA, Guzman A del CT. Tratamiento antiplaquetario prequirúrgico y postquirúrgico. RECIMUNDO [Internet]. 2019 Dec 4 [cited 2022 Jul 17];3(3):906–18. Available from: https://recimundo.com/index.php/es/article/view/636
Antonio J, Romero S, Yulisa ;, Arana Alcivar V, Dámarys ;, León KS, et al. Agentes antiagregantes en los síndromes coronarios agudos. RECIMUNDO. 2020 Feb 5;4(1):71–83.
Laine M, Frère C, Bonello L. Principales medicamentos antiagregantes: manejo, vigilancia y gestión de las complicaciones. EMC - Tratado de Medicina. 2020 Aug 1;24(3):1–7.
Dobesh PP, Finks SW, Trujillo TC. Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. Clinical Therapeutics. 2020 Oct 1;42(10):2084–97.
Al-Abdouh A, Abusnina W, Mhanna M, Radideh Q, Alzu H, Rmilah AA, et al. P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis. Current Problems in Cardiology. 2022 Jun 25;101292.
Yeung J, Li W, Holinstat M. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacological Reviews [Internet]. 2018 Jul 1 [cited 2022 Jul 5];70(3):526–48. Available from: https://pharmrev.aspetjournals.org/content/70/3/526
Passacquale G, Sharma P, Perera D, Ferro A. Antiplatelet therapy in cardiovascular disease: Current status and future directions. Br J Clin Pharmacol [Internet]. 2022 Jun 1 [cited 2022 Jul 8];88(6):2686–99. Available from: https://pubmed.ncbi.nlm.nih.gov/35001413/
Barnes GD. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology: the American Society of Hematology Education Program [Internet]. 2020 Dec 12 [cited 2022 Jul 5];2020(1):642. Available from: /pmc/articles/PMC7727581/
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine [Internet]. 2018 Oct 18 [cited 2022 Jul 9];379(16):1509–18. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1805819
Grupo Colaborativo de Estudio ASCEND. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine [Internet]. 2018 Oct 18 [cited 2022 Jul 9];379(16):1529–39. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1804988
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2018 Sep 9 [cited 2022 Jul 9];392(10152):1036. Available from: /pmc/articles/PMC7255888/
Li XY, Li L, Na SH, Santilli F, Shi Z, Blaha M. Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease. American Journal of Preventive Cardiology [Internet]. 2022 Sep [cited 2022 Jul 9];11:100363. Available from: /pmc/articles/PMC9214826/
Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nature Reviews Cardiology 2019 16:11 [Internet]. 2019 Jun 26 [cited 2022 Jul 9];16(11):675–86. Available from: https://www.nature.com/articles/s41569-019-0225-y
Patti G, Micieli G, Cimminiello C, Bolognese L. The Role of Clopidogrel in 2020: A Reappraisal. Cardiovascular Therapeutics. 2020;2020.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine [Internet]. 2016 Jul 7 [cited 2022 Jul 17];375(1):35–43. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1603060
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine [Internet]. 2019 Oct 3 [cited 2022 Jul 17];381(14):1309–20. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1908077
Al-Abdouh A, Abusnina W, Mhanna M, Radideh Q, Alzu H, Rmilah AA, et al. P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis. Current Problems in Cardiology. 2022 Jun 25;101292.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 LA CIENCIA AL SERVICIO DE LA SALUD Y NUTRICIÓN
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
